Navigation Links
Insulet Corporation Announces Pricing of Secondary Public Offering

BEDFORD, Mass., Nov. 7 /PRNewswire-FirstCall/ -- Insulet Corporation, (Nasdaq: PODD), the manufacturer and marketer of the OmniPod(R) Insulin Management System, today announced the pricing of its public offering of 4,898,398 shares of common stock at $23.25 per share, all of which are being sold by selling stockholders. Insulet will not receive any proceeds from the sale of shares by the selling stockholders. Insulet has granted to the underwriters an option to purchase up to 734,759 shares of its common stock at the public offering price to cover any over-allotments.

J.P. Morgan Securities Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated are acting as joint book-running managers, and Leerink Swann LLC, Thomas Weisel Partners LLC and Canaccord Adams Inc. are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission and has become effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer or sale will be made only by means of the written prospectus forming part of the effective registration statement.

A copy of the prospectus relating to the offering may be obtained by contacting one of the following:

J.P. Morgan Securities Inc., National Statement Processing, Prospectus

Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by

calling (718) 242-8002.

Merrill Lynch, Pierce, Fenner & Smith Incorporated, World Financial

Center, 250 Vesey Street, New York, NY 10080 or by calling (212) 449-1000.

About Insulet Corporation

Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully- automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet is based in Bedford, MA.

For more information about Insulet Corporation and the OmniPod System, please visit our website at


Stephanie Marks for Insulet Corporation

877-PODD-IR1 (877-763-3471)

SOURCE Insulet Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Insulet Awarded National Accreditation for Excellence by Community Health Accreditation Program
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. Brooke Franchise Corporation Announces Selected July Results
4. MedThink Communications Retained by NanoBio Corporation
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
8. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
9. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
10. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... Libertyville, IL (PRWEB) , ... December 01, 2015 ... ... catheters, keeping their independence is everything. That is why Hollister Incorporated has launched ... excited to offer this next product in the VaPro touch free catheter portfolio,” ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... , ... December 01, 2015 , ... With FCPX ... and with full control over customization, the possibilities are truly endless, all with a ... randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, all ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ... the company will present at the LD Micro Main Event. ... Sunset Boulevard Hotel in Los Angeles, CA. ... present on Thursday, December 3, at 9:00 am Pacific time ... at least 10 minutes prior to the start of the ...
(Date:12/1/2015)... Dec. 1, 2015   MabVax Therapeutics Holdings, Inc ... announces it has filed an Investigational New Drug Application ... for the Company,s lead fully human antibody product HuMab ... MabVax plans to initiate the Phase I clinical trial ... --> The planned Phase I trial will ...
(Date:12/1/2015)... 2015   Craneware, Inc ., the healthcare ... announced the company will showcase a new version ... solution at the American Society for Health-System ... The new features are focused on simplifying and ... managing enterprise-wide pharmacy charges to ensure compliance and ...
Breaking Medicine Technology: